Evidence map›Paper›PMID 37830409›Full record

ArticleThe Journal of dermatology2024

Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with possible complication of thrombotic microangiopathy.

Yumi Ito, Saki Takeuchi, Takahisa Tozawa, Satoko Hisada, Yoshihiro Yamada, Masanari Kodera, Masahiro Kobayashi, Mizuho Shirahata, Akihiro Matsubara

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yumi ItoDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0003-2766-3659
Saki TakeuchiDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Takahisa TozawaDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Satoko HisadaDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Yoshihiro YamadaDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Masanari KoderaDepartment of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Masahiro KobayashiDepartment of Respiratory Medicine, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Mizuho ShirahataDepartment of Hematology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.
Akihiro MatsubaraDepartment of Dermatology, Nagoya City University, Nagoya, Japan.ORCID https://orcid.org/0000-0002-2454-5465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case study illustrates a 63-year-old Japanese woman who presented with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. She was administered a therapeutic regimen consisting of corticosteroids, tacrolimus, and cyclophosphamide. However, after a month of treatment, symptoms of confusion and depressive tendencies emerged, followed by the manifestation of hematuria, thrombocytopenia, and fragmented erythrocytes. A disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13 activity was 45%. Thrombotic microangiopathy was contemplated, yet a definitive diagnosis remained elusive. She died 2 months after admission. Although the occurrence of thrombotic microangiopathy in patients with dermatomyositis is rare, the prognosis is poor, emphasizing the importance of prompt diagnosis and treatment.

Indexed as

DermatomyositisThrombotic MicroangiopathiesCyclophosphamideFemaleHumansMiddle AgedPrognosisTacrolimusCyclophosphamideTacrolimusa disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13hematuriaimmunosuppressive therapypsychiatric symptomthrombocytopenia

Identifiers

PMID37830409
PMCPMC11483893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.